Natixis Advisors LLC Purchases 10,462 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Natixis Advisors LLC grew its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 19.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,706 shares of the medical device company’s stock after purchasing an additional 10,462 shares during the quarter. Natixis Advisors LLC owned about 0.10% of Tandem Diabetes Care worth $2,702,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of TNDM. Assetmark Inc. purchased a new stake in Tandem Diabetes Care during the 3rd quarter worth about $29,000. ORG Wealth Partners LLC bought a new position in shares of Tandem Diabetes Care in the third quarter valued at approximately $30,000. ORG Partners LLC purchased a new position in Tandem Diabetes Care during the second quarter valued at approximately $31,000. Waldron Private Wealth LLC bought a new stake in Tandem Diabetes Care during the 3rd quarter worth approximately $50,000. Finally, Headlands Technologies LLC lifted its stake in Tandem Diabetes Care by 110.0% in the 2nd quarter. Headlands Technologies LLC now owns 2,060 shares of the medical device company’s stock worth $83,000 after purchasing an additional 1,079 shares in the last quarter.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now owns 195,190 shares in the company, valued at approximately $5,855,700. This represents a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.20% of the stock is currently owned by corporate insiders.

Tandem Diabetes Care Price Performance

Shares of Tandem Diabetes Care stock opened at $30.81 on Monday. The firm has a market cap of $2.02 billion, a PE ratio of -15.96 and a beta of 1.36. The company’s fifty day simple moving average is $36.16 and its two-hundred day simple moving average is $41.24. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12-month low of $18.45 and a 12-month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $243.97 million during the quarter, compared to analyst estimates of $224.14 million. During the same quarter in the prior year, the company posted ($0.38) EPS. Tandem Diabetes Care’s quarterly revenue was up 31.4% compared to the same quarter last year. As a group, equities analysts expect that Tandem Diabetes Care, Inc. will post -1.73 EPS for the current year.

Analyst Ratings Changes

TNDM has been the subject of several research analyst reports. Wells Fargo & Company lifted their price objective on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group began coverage on shares of Tandem Diabetes Care in a research report on Thursday, August 8th. They issued a “buy” rating and a $57.00 price objective on the stock. Morgan Stanley reiterated an “equal weight” rating and set a $45.00 target price on shares of Tandem Diabetes Care in a research report on Monday, September 23rd. UBS Group raised shares of Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Finally, Barclays lifted their price objective on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.25.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.